New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:38 EDTFRX, GS, ACT, MSMorgan Stanley, Goldman said to switch fees for deal credit, Bloomberg says
Morgan Stanley (MS) and Goldman Sachs (GS) both decided last month that it was worth losing millions of dollars in fees to get credit on the $25B sale of Forest Laboratories (FRX) to Actavis (ACT), according to Bloomberg, citing four people with knowledge of the matter. The sources say that neither investment bank actually had a role on the deal. Reference Link
News For MS;GS;FRX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 12, 2014
07:10 EDTMSMorgan Stanley downgraded to Neutral from Buy at Buckingham
Subscribe for More Information
December 11, 2014
19:06 EDTACTActavis confirms court ruling to require continued distribution of Namenda IR
Subscribe for More Information
10:17 EDTGS, MSFINRA fines Barclays Capital, Citigroup Global Markets, others $43.5M total
FINRA announced that it has fined 10 firms a total of $43.5M for allowing their equity research analysts to solicit investment banking business and for offering favorable research coverage in connection with the 2010 planned initial public offering of Toys"R"Us. FINRA fined the following firms. Barclays Capital (BCS) - $5M; Citigroup Global Markets (C) $ 5M; Credit Suisse Securities (CS) $5M; Goldman, Sachs & Co. (CS) $5M; JP Morgan Securities LLC (JPM) $5M; Deutsche Bank Securities Inc. (DB) $4M; Merrill Lynch, Pierce, Fenner & Smith Inc. (BAC) $4M; Morgan Stanley & Co., LLC (MS) $4M; Wells Fargo Securities, LLC (WFC) $4M; Needham & Company LLC $2.5M. In addition, FINRA found that six of the 10 firms Barclays, Citigroup, Credit Suisse, Goldman Sachs, JP Morgan and Needham had inadequate supervisory procedures related to research analyst participation in investment banking pitches. Toys"R"Us and its sponsors offered each of the 10 firms various roles in the IPO but it eventually decided not to proceed with the offering. In settling this matter, the 10 firms neither admitted nor denied the charges, but consented to the entry of FINRA's findings.
07:49 EDTGSThe New York Times to hold a conference
Subscribe for More Information
December 10, 2014
16:24 EDTGSGoldman Sachs reports 10.7% passive stake in Navios Maritime Midstream
Subscribe for More Information
11:40 EDTACTActavis management to meet with Sterne Agee
Subscribe for More Information
11:20 EDTMSMorgan Stanley pays $4M to SEC for violating market access rule
Subscribe for More Information
10:00 EDTGSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:33 EDTACTActavis launches generic version of Celebrex
Actavis (ACT) announced that it has launched a generic version of Celebrex 50 mg, 100 mg, 200 mg and 400 mg capsules, as part of a settlement agreement with Pfizer (PFE). Celebrex is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. For the 12-month period ending June 30, 2014, Celebrex had U.S. sales of approximately $2.4 billion, according to IMS Health data.
06:57 EDTGSGoldman Sachs downgraded at Susquehanna
As previously reported, Susquehanna downgraded Goldman Sachs to Neutral from Positive. The firm downgraded shares based on full valuation and expectations the fall in energy prices will weigh on high yield and loan volumes into 2015, and pressure the debt portion of investing and lending in the secondary markets. Price target lowered to $200 from $218.
06:32 EDTGSGoldman Sachs downgraded to Neutral from Positive at Susquehanna
Subscribe for More Information
December 9, 2014
14:57 EDTMS, GSFed to propose rulemaking on risk-based capital surcharges for GSIB banks
Subscribe for More Information
14:42 EDTGS, MSFed sees setting capital surcharge up to 4.5% for big U.S. banks, Bloomberg says
Bloomberg cites surcharge estimates in Federal Reserve staff memo. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
09:31 EDTACTZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:14 EDTACTAllergan price target raised to $245 from $210 at Citigroup
Subscribe for More Information
December 8, 2014
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:55 EDTGSGoldman Sachs ordered to pay $7.6M in wrongful discharge claim
Subscribe for More Information
11:30 EDTACTLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
06:35 EDTMS, GSValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:21 EDTMSDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use